Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CT

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Pancreatic cancer remains a major health problem, and only less than 20% of patients have resectable disease at the time of initial diagnosis. Systemic chemotherapy is often used in the patients with borderline resectable, locally advanced unresectable disease and metastatic disease. CT is often used to assess for therapeutic response; however, conventional imaging including CT may not correctly reflect treatment response after chemotherapy. Dual-energy (DE) CT can acquire datasets at two different photon spectra in a single CT acquisition, and permits separating materials and extract iodine by applying a material decomposition algorithm. Quantitative iodine mapping may have an added value over conventional CT imaging for monitoring the treatment effects in patients with pancreatic cancer and potentially serve as a unique biomarker for treatment response. In this pictorial essay, we will review the technique for iodine quantification of pancreatic cancer by DECT and discuss our observations of iodine quantification at baseline and after systemic chemotherapy with conventional cytotoxic agents, and illustrate example cases.

Original languageEnglish (US)
Pages (from-to)445-456
Number of pages12
JournalAbdominal Radiology
Issue number2
StatePublished - Feb 1 2018


  • Chemotherapy
  • Dual-energy CT
  • Iodine uptake
  • Pancreatic adenocarcinoma
  • Treatment response

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology


Dive into the research topics of 'Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CT'. Together they form a unique fingerprint.

Cite this